Court Upheld Johnson & Johnson Patent Acquisition Ruling
The appellate appeal tests if monopolization claims require proving specific intent by the acquirer.
Updated on Sept. 22, 2026 in Healthcare
Live Poll
Should federal antitrust law require proof of specific intent to exclude rivals to establish illegal monopolization?
CareFirst appealed a February 10, 2026, ruling that granted summary judgment to Johnson & Johnson regarding the acquisition of four Momenta Pharmaceuticals manufacturing patents. The case examines whether the Sherman Act requires proof of specific intent to exclude competitors.
Why it matters
The outcome will clarify the evidentiary threshold for monopolization claims, significantly impacting how companies evaluate antitrust risk during intellectual property acquisitions. The Federal Trade Commission has intervened, arguing that such claims should not hinge on proving specific intent.
The dispute centers on the acquisition of 4 Momenta Pharmaceuticals manufacturing patents, which the U.S. District Court for the Eastern District of Virginia ruled did not violate Section 2 of the Sherman Act due to insufficient evidence of intent.
The players
Johnson & Johnson
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
CareFirst
A health insurer currently challenging patent acquisition practices under federal antitrust laws.
Federal Trade Commission
The federal agency tasked with protecting consumers and ensuring competition by enforcing antitrust laws.
The details
The district court concluded that there was insufficient evidence to demonstrate that Johnson & Johnson intended to exclude competitors when it acquired the four patents. CareFirst is challenging this finding, arguing that the lower court incorrectly mandated a specific-intent requirement for antitrust violations. The Federal Trade Commission filed an amicus brief supporting the view that monopolization under the Sherman Act does not require evidence of specific intent.
Timeline
December 2025: Portions of the antitrust claims survived initial summary judgment.
January 14, 2026: The U.S. District Court for the Eastern District of Virginia granted summary judgment to Johnson & Johnson.
February 10, 2026: The court directed the entry of final judgment for Johnson & Johnson.
October 8, 2026: CareFirst is scheduled to file its reply brief.
Market Landscape
This case follows a pattern of heightened scrutiny regarding how large corporations consolidate intellectual property. The dispute specifically tests the application of Section 2 of the Sherman Act in the context of patent acquisitions.
Operators should monitor this case as it could lower the threshold for antitrust litigation in M&A deals involving patent portfolios. Legal counsel should evaluate how internal documentation regarding acquisition intent may be scrutinized under evolving interpretations of Section 2.
The takeaway
The appellate outcome will establish whether companies must prove a lack of anticompetitive intent during patent acquisitions. Keep a close watch on the October 8, 2026, filing for signs of how the court addresses the Federal Trade Commission's stance on monopolization intent.
What happens next
CareFirst must submit its reply brief by October 8, 2026.
Further reading
For broader trends in industry regulation, visit the Healthcare section.
Live Poll
Should federal antitrust law require proof of specific intent to exclude rivals to establish illegal monopolization?
